The authors followed for 24 months 403 post-menopausal women enrolled in the Osteoporosis Prevention Using Soy (OPUS) study and analyzed their quality of life using the Menopause-Specific Quality-of-Life (MENQOL) questionnaire to evaluate vasomotor, psychosocial, physical & sexual domains. Compared to placebo, neither 80mg nor 120mg of soy isoflavones comprised mostly of daidzein made a dramatic impact on MENQOL scores. Importantly, there was no difference in thickness of endometrial lining as measured by transvaginal ultrasound.
To be fair, soybeans contain genistein & glycitein isoflavones in addition to daidzein. Moreover, the women studied in this group were 5 years post-menopausal and thus, conceivably past the worst of their symptoms since most reported not being bothered by either vasomotor or sexual symptoms at baseline. The participants were also of normal weight so it's possible that these results won't apply to the two-thirds of the population that are either overweight or obese.
Nevertheless, while soy supplementation may not have worked in this particular trial, there is no reason to prohibit consumption of soybeans as part of a healthy diet. Perhaps some women will receive adequate benefit when other isoflavones are consumed, rather than a single one in isolation. Certainly, soybeans are a good source of complete protein & fiber w/o the saturated fat found in land animal-based proteins.
Tweet
This site complies with the HONcode standard for trustworthy health information:
verify here.
No comments:
Post a Comment